Acutus Medical Announces Acceptance of the AcQForce Flutter Abstract for Presentation during the Late-Breaking Clinical Trials and First Report Investigations sessions at the 2023 AF Symposium

Rhea-AI Summary

Acutus Medical (Nasdaq: AFIB) announced the acceptance of its AcQForce Flutter abstract for presentation at the AF Symposium in Boston on February 3, 2023. The abstract details the clinical results of the AcQForce Flutter trial, which utilizes the AcQBlate Force Sensing Ablation Catheter. This catheter features a gold tip electrode with four times the thermal conductivity of platinum, enabling efficient energy delivery at lower temperatures. This marks Acutus' first PMA submission and first presentation at a Late-Breaking Clinical Trials session.

Positive

• AcQForce Flutter abstract accepted for presentation at AF Symposium, showcasing successful trial results.
• Introduction of the AcQBlate Force Sensing Ablation Catheter, enhancing treatment efficiency with gold tip technology.

Negative

• None.

CARLSBAD, Calif., Dec. 29, 2022 (GLOBE NEWSWIRE) -- Acutus Medical, Inc. (“Acutus”) (Nasdaq: AFIB), an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, today announced the acceptance of the AcQForce Flutter abstract titled “AcQForce Flutter Trial Clinical Results: Force Sensing RF Ablation with Low Flow Gold Tip Catheter for Typical Flutter” for presentation during the Late-Breaking Clinical Trials and First Report Investigations session at the AF Symposium in Boston. This abstract – including full study results - will be presented on Friday, February 3, 2023.

The AcQForce Flutter clinical study was submitted to the FDA as part of Acutus’ PMA submission for the AcQBlate Force Sensing Ablation Catheter, the only force-sensing ablation catheter with a gold tip electrode, and System. The irrigated gold tip ablation catheter has 4x thermal conductivity compared to platinum catheters, which allows for significantly more energy delivery at a lower temperature and requires less saline flow.¹ This is the first PMA submission by Acutus and the first time the company is presenting at a Late-Breaking Clinical Trials session.

To learn more about Acutus Medical’s complete portfolio of diagnostic, access and therapy products, please visit https://acutusmedical.com.

References
1. Linhart M. et al., Superiority of Gold Compared to Platinum Tip Irrigated Catheter Ablation of the Pulmonary Veins and the Cavotricuspid Isthmus: A Randomized Study Comparing Tip Temperatures and Cooling Flow Requirements. J Cardiovasc Electrophysiol. 2012 Jul; 23(7): 717–21

About Acutus Medical
Acutus Medical is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. Acutus is committed to advancing the field of electrophysiology with a unique array of products and technologies which will enable more physicians to treat more patients more efficiently and effectively. Through internal product development, acquisitions and global partnerships, Acutus has established a global sales presence delivering a broad portfolio of highly differentiated electrophysiology products that provide its customers with a complete solution for catheter-based treatment of cardiac arrhythmias. Founded in 2011, Acutus is based in Carlsbad, California.

About AF Symposium
The AF Symposium is an intensive three-day symposium that brings together the world's leading medical scientists to share, in a highly interactive environment, the most recent advances in the field of atrial fibrillation. The AF Symposium was initiated in 1995 in response to the growing epidemic of atrial fibrillation. Over the past 28 years, the meeting has become a major scientific forum at which health care professionals have a unique opportunity to learn about advances in research and therapeutics directly from many of the most eminent investigators in the field.

Follow Acutus Medical on: Twitter, LinkedIn, YouTube and Facebook.

Investor Contact
Caroline Corner
415-202-5678
caroline.corner@westwicke.com

Media Contact
Peter Neems
442-232-6094
peter.neems@acutus.com

FAQ

What is the AcQForce Flutter trial about?

The AcQForce Flutter trial focuses on evaluating the AcQBlate Force Sensing Ablation Catheter's effectiveness in treating typical flutter using force-sensing technology.

When will the AcQForce Flutter trial results be presented?

The results of the AcQForce Flutter trial will be presented on February 3, 2023, at the AF Symposium in Boston.

What is unique about the AcQBlate Force Sensing Ablation Catheter?

The AcQBlate catheter features a gold tip electrode with four times the thermal conductivity of platinum, allowing for more efficient energy delivery during procedures.

What is the significance of the PMA submission by Acutus?

The PMA submission is significant as it represents Acutus' first foray into regulatory approvals, potentially leading to commercialization of their innovative ablation technology.

How does the AcQForce Flutter trial impact Acutus Medical's future?

Successful results from the AcQForce Flutter trial could enhance Acutus Medical's market position and drive further adoption of its innovative catheter technologies.